SCHEDULE: Leviticus Partners Discloses 7.6% Stake in Harvard Bioscience

Leviticus Partners LP has disclosed a 7.6% beneficial ownership stake in Harvard Bioscience Inc., holding 3,401,601 common shares.

Summary

• Leviticus Partners LP, an investment adviser, reported beneficial ownership of 3,401,601 shares of Harvard Bioscience Inc. common stock.
• This stake represents 7.6% of the total class of securities.
• Adam M Hutt, Managing Member of Leviticus Partners LP, has sole voting and sole dispositive power over all 3,401,601 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, indicating an institutional investor's confidence in Harvard Bioscience Inc. without suggesting any immediate activist intentions.

Positives

• A significant stake by an investment adviser like Leviticus Partners LP may signal confidence in Harvard Bioscience Inc.'s future prospects.
• The filing indicates the stake is for investment purposes in the ordinary course of business, not for activism or control changes.

Risks

• No specific risks related to Harvard Bioscience Inc. are detailed in this ownership disclosure.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that a significant passive stake by an investment adviser in a bioscience company like Harvard Bioscience Inc. can be interpreted by the market as a vote of confidence in the company's long-term strategy and market position within the life sciences tools and services sector. Such disclosures often attract attention from other institutional investors, potentially influencing trading volumes and investor sentiment.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially attract further investment, positively impacting share value.

Key Dates

Keywords

Harvard Bioscience Inc., Leviticus Partners LP, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Equity Stake, SEC Filing